Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Glatiramer acetate is a synthetic mixture of polypeptides composed of four naturally occurring amino acids (L-glutamic acid, L-alanine, L-tyrosine, and L-lysine) designed to mimic myelin basic protein. It is an immunomodulatory agent used for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The precise mechanism of action is not fully understood but it is believed to work by modifying immune processes involved in MS pathogenesis. Glatiramer acetate binds to major histocompatibility complex (MHC) class II molecules on antigen-presenting cells and competes with myelin basic protein for binding sites. This results in the inhibition of pro-inflammatory Th1 responses and induction of anti-inflammatory Th2 suppressor T-cells that can cross the blood-brain barrier and secrete anti-inflammatory cytokines. It may also induce regulatory T-cells that help suppress MS activity[2][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on glatiramer acetate.